US20030135060A1 - Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives - Google Patents
Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives Download PDFInfo
- Publication number
- US20030135060A1 US20030135060A1 US09/965,774 US96577401A US2003135060A1 US 20030135060 A1 US20030135060 A1 US 20030135060A1 US 96577401 A US96577401 A US 96577401A US 2003135060 A1 US2003135060 A1 US 2003135060A1
- Authority
- US
- United States
- Prior art keywords
- dichloro
- solution
- anthracenone
- substituted
- reaction mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract description 12
- 230000003859 lipid peroxidation Effects 0.000 title abstract description 12
- 238000003786 synthesis reaction Methods 0.000 title abstract description 12
- -1 10-substituted 1,5-dichloro-9(10H)-anthracenone Chemical class 0.000 title description 11
- 230000001472 cytotoxic effect Effects 0.000 title description 3
- 238000011156 evaluation Methods 0.000 title description 2
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- HNDVRSZCIGFZGL-UHFFFAOYSA-N 1,5-dichloro-10h-anthracen-9-one Chemical group O=C1C2=C(Cl)C=CC=C2CC2=C1C=CC=C2Cl HNDVRSZCIGFZGL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 208000019065 cervical carcinoma Diseases 0.000 claims abstract description 4
- 230000012010 growth Effects 0.000 claims abstract description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims abstract 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- 239000011541 reaction mixture Substances 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 239000012528 membrane Substances 0.000 abstract description 3
- 230000002468 redox effect Effects 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 44
- MRVNKBNZHOHVER-UHFFFAOYSA-N 2h-anthracen-1-one Chemical class C1=CC=C2C=C3C(=O)CC=CC3=CC2=C1 MRVNKBNZHOHVER-UHFFFAOYSA-N 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 9
- JUCPFGUIXOGANT-UHFFFAOYSA-N 10-bromo-1,5-dichloro-10h-anthracen-9-one Chemical compound O=C1C2=C(Cl)C=CC=C2C(Br)C2=C1C=CC=C2Cl JUCPFGUIXOGANT-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 0 *C(c1cccc(Cl)c11)c(c(Cl)ccc2)c2C1=* Chemical compound *C(c1cccc(Cl)c11)c(c(Cl)ccc2)c2C1=* 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 5
- 229960001156 mitoxantrone Drugs 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- XZGFTCILNMUBQK-UHFFFAOYSA-N 1,5-dichloro-10-(2-methylanilino)-10h-anthracen-9-one Chemical compound CC1=CC=CC=C1NC1C2=C(Cl)C=CC=C2C(=O)C2=C(Cl)C=CC=C21 XZGFTCILNMUBQK-UHFFFAOYSA-N 0.000 description 4
- CWKFVSHEGOEMPV-UHFFFAOYSA-N 1,5-dichloro-10-(2-methylpropoxy)-10h-anthracen-9-one Chemical compound C1=CC(Cl)=C2C(OCC(C)C)C3=CC=CC(Cl)=C3C(=O)C2=C1 CWKFVSHEGOEMPV-UHFFFAOYSA-N 0.000 description 4
- QAKCGIAZFBUFDQ-UHFFFAOYSA-N 1,5-dichloro-10-propoxy-10h-anthracen-9-one Chemical compound C1=CC(Cl)=C2C(OCCC)C3=CC=CC(Cl)=C3C(=O)C2=C1 QAKCGIAZFBUFDQ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005556 structure-activity relationship Methods 0.000 description 3
- HQRTWQPBVWXBJS-UHFFFAOYSA-N 1,5-dichloro-10-(3-methylanilino)-10h-anthracen-9-one Chemical compound CC1=CC=CC(NC2C3=C(Cl)C=CC=C3C(=O)C3=C(Cl)C=CC=C32)=C1 HQRTWQPBVWXBJS-UHFFFAOYSA-N 0.000 description 2
- PJNYLRWEAHGJFU-UHFFFAOYSA-N 1,5-dichloro-10-(4-methylanilino)-10h-anthracen-9-one Chemical compound C1=CC(C)=CC=C1NC1C2=C(Cl)C=CC=C2C(=O)C2=C(Cl)C=CC=C21 PJNYLRWEAHGJFU-UHFFFAOYSA-N 0.000 description 2
- DKXQGYAUOLBGHX-UHFFFAOYSA-N 1,5-dichloro-10-(diethylamino)-10h-anthracen-9-one Chemical compound C1=CC(Cl)=C2C(N(CC)CC)C3=CC=CC(Cl)=C3C(=O)C2=C1 DKXQGYAUOLBGHX-UHFFFAOYSA-N 0.000 description 2
- DCSRZCOZWQBBHV-UHFFFAOYSA-N 1,5-dichloro-10-ethoxy-10h-anthracen-9-one Chemical compound C1=CC(Cl)=C2C(OCC)C3=CC=CC(Cl)=C3C(=O)C2=C1 DCSRZCOZWQBBHV-UHFFFAOYSA-N 0.000 description 2
- VWHNEGPFMABKLA-UHFFFAOYSA-N 1,5-dichloro-10-methoxy-10h-anthracen-9-one Chemical compound C1=CC(Cl)=C2C(OC)C3=CC=CC(Cl)=C3C(=O)C2=C1 VWHNEGPFMABKLA-UHFFFAOYSA-N 0.000 description 2
- UNJGJWHAIMNQJX-UHFFFAOYSA-N 1,5-dichloro-10-propan-2-yloxy-10h-anthracen-9-one Chemical compound C1=CC(Cl)=C2C(OC(C)C)C3=CC=CC(Cl)=C3C(=O)C2=C1 UNJGJWHAIMNQJX-UHFFFAOYSA-N 0.000 description 2
- CSXDVOKDSMCSJV-UHFFFAOYSA-N 10-butoxy-1,5-dichloro-10h-anthracen-9-one Chemical compound C1=CC(Cl)=C2C(OCCCC)C3=CC=CC(Cl)=C3C(=O)C2=C1 CSXDVOKDSMCSJV-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 2
- 150000001454 anthracenes Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000012925 biological evaluation Methods 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- HDAAOKRJILHTIA-UHFFFAOYSA-N 1,5-dichloro-10-phenylmethoxy-10h-anthracen-9-one Chemical compound C1=2C(Cl)=CC=CC=2C(=O)C2=C(Cl)C=CC=C2C1OCC1=CC=CC=C1 HDAAOKRJILHTIA-UHFFFAOYSA-N 0.000 description 1
- MQIUMARJCOGCIM-UHFFFAOYSA-N 1,5-dichloroanthracene-9,10-dione Chemical compound O=C1C2=C(Cl)C=CC=C2C(=O)C2=C1C=CC=C2Cl MQIUMARJCOGCIM-UHFFFAOYSA-N 0.000 description 1
- AYDNUUZHQKPRKA-UHFFFAOYSA-N 1,8-dichloro-10h-anthracen-9-one Chemical class C1C2=CC=CC(Cl)=C2C(=O)C2=C1C=CC=C2Cl AYDNUUZHQKPRKA-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical group C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 101100438156 Arabidopsis thaliana CAD7 gene Proteins 0.000 description 1
- 101150071647 CAD4 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101100322652 Catharanthus roseus ADH13 gene Proteins 0.000 description 1
- 101100087088 Catharanthus roseus Redox1 gene Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical class C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006454 non catalyzed reaction Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Definitions
- Anthracene and anthracenone derivatives have been the subject of extensive research mainly due to their well-recognized biological importance and the significant biological applications.
- potential drug targets only present in cancerous cells have surfaced, the design of a drug which is selectively toxic to a tumor and not to the host organism is still very difficult have reported by Krapcho A. P., et al., J. Med. Chem., vol. 41, pp. 5429-5444 (1998).
- the present invention is described the novel 1,5-dichloro-9(10H)-anthracenones bearing O-linked and N-linked substituents compounds and analogs thereof having therapeutic utility with respect to tumor conditions or antioxidant activity.
- many of the improved anthracenone compounds provided for according to the practice of the invention are effective at low concentrations for treatment of patients suffering from tumor conditions or antioxidant activity.
- an anthracene compound according to formula 3 as defined below and shown in FIG. 1, said compound containing substituent R 1 , wherein R 1 represents oxygen, nitrogen.
- the substituent R 2 wherein R 2 represents a branched or straight chain alkyl group having from 1 to 4 carbon atoms, said alkyl group being substituted with at least one substituent selected from the group consisting of a carboxyl, hydrogen, substituted phenyl, benzyl and substituted benzyl groups or a substituted phenyl group.
- FIG. 1 shows the structural of 10-substituted 1,5-dichloro-9(10H)-anthracenones of formula 3.
- FIG. 2 shows the structural of 9-acyloxy 1,5-dichloroanthracenes and 9-acyloxy 1,8-dichloroanthracene.
- FIG. 3 shows the synthesis step of the target 10-substituted 1,5-dichloro-9(10H)-anthracenones of formula 3.
- FIG. 4 shows X-ray crystal structure of compounds 6.
- the compound of this invention will include various excipients; carriers or diluents and pharmaceutically approved pH of processed salts in accordance to necessity to form composition with therapeutic efficacy.
- Such pharmaceutical preparation could be in solid form for oral and rectum administration; liquid form or non-intestinal injection form; or ointment form for direct application on affected part.
- Such solid forms are manufactured according to common pharmaceutical preparation methods, which will include disintegrant like starch; sodium carboxymethyl cellulose, adhesive like ethanol; glycerine, or magnesium stearic acid; lactose to make into pharmaceutical preparation like tablets or filled into capsules or suppository.
- Solution or saline that include this invention compound as ingredient could use buffers of phosphoric nature to adjust the pH to suitable level, before adding adjutant; emulsifier to produce injection dose or other liquid preparation.
- This invention compound or pharmaceutical manufacturing could mixed synthetic acid salts with various fundamental preparations to form ointments according to known pharmaceutical manufacturing methods.
- Pharmaceutical compounds manufactured with this invention compound being the major ingredient could be used on mammals to produce the efficacy of this main ingredient. General dosage could be adjusted according to the degree of symptoms, and normally a person will require 50 to 300 mg each time, three times per day.
- Rat brain homogenate was prepared from the brains of freshly killed Wistar rats and its peroxidation in the presence of iron ions was measured by the thiobarbituric acid (TB A) method as described. The extent of lipid peroxidation was estimated as thiobarbituric acid-reactive substances and was read at 532 nm in a spectrophotometer (Shimnadzu UV-160). The results of this assay are provided in tables 2 and 3.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- 1. Field of the Invention
- The synthesis of a series of 1,5-dichloro-9(10H)-anthracenones bearing O-linked and N-linked substituents in the 10-position are described. These compounds were evaluated for their ability to inhibit the growth of the tumor, and lipid peroxidation in model membranes.
- Description of the prior art. Anthracenone derivatives display potent and selective antitumor activity, but their mechanism of action is not clearly established yet. Despite structural similarities between the substitutents anthracenone nucleus and molecules possessing known antitumor activity, antiproliferative, antipsoriatic, antiinflammnatory, or antioxidant activity, these agents form a distinct mechanictic class. Perry P. J., et al., J. Med. Chem., vol. 41, pp. 3253-3260,4873-4884 (1998); Perry P. J., et al., J. Med. Chem., vol. 42, pp. 2679-2684 (1999). Anthracene and anthracenone derivatives have been the subject of extensive research mainly due to their well-recognized biological importance and the significant biological applications. Although potential drug targets only present in cancerous cells have surfaced, the design of a drug which is selectively toxic to a tumor and not to the host organism is still very difficult have reported by Krapcho A. P., et al., J. Med. Chem., vol. 41, pp. 5429-5444 (1998).
- We have previously shown that 9-
acyloxy 1,5-dichloroanthracenes at WO 0061536 and 9-acyloxy 1,8-dichloroanthracenes on Chem. Pharm. Bull., vol. 49(8), pp. 969-973(2001). In the previous papers, we described the synthesis, biological evaluation and structure-activity relationships for 9-acyloxy derivatives. In order to provide further insight into anthracene and anthracenone pharmacophore, the involvement of free radicals and antiproliferative activity, we examined the effects of introducing electron-donating 10-oxy and 10-N substituents to see where replacement of the electron-withdrawing carbonyl of the earlier series can provide analogs with both potent antioxidant and antiproliferative activities. Despite the extensive and long-standing therapeutic utilization of anthracenones, their mechanism of action is still uncertain. A large body of evidence is consistent with a fundamental role of oxygen radicals in the induction of skin inflammation by anthracenes of Müller K., Biochem. Pharmacol., vol. 53, pp. 1215-1221 (1997). - The mode of action of anthracenones leads to the conclusion that no single mechanism is predominantly operative and oxygen radicals play a crucial role in the proinflammatory action. As noted above, cancer is typically characterized by hyperproliferative component. There is thus a continuing need for effective compounds that address these aspects of cancer disease. To gain a wider understanding of the involvement of radicals in the action of anthracenone-derived agents, several related compounds bearing selected characteristic functional groups were designed. The approach was to develop structure-activity relationships (SARs) of 9(10H)-anthracenone analogs with redox-active centers attached to the anthraquinone skeleton through spacer side chains at position 10, together with substituents with DNA-binding affinity. This paper describes the design and synthesis of anthracenones that incorporate in their structure a potential antioxidant component and the results of relevant biologic studies.
- The present invention is described the
novel 1,5-dichloro-9(10H)-anthracenones bearing O-linked and N-linked substituents compounds and analogs thereof having therapeutic utility with respect to tumor conditions or antioxidant activity. In particular, many of the improved anthracenone compounds provided for according to the practice of the invention are effective at low concentrations for treatment of patients suffering from tumor conditions or antioxidant activity. - Accordingly, in one embodiment of the invention, there is provided an anthracene compound according to
formula 3 as defined below and shown in FIG. 1, said compound containing substituent R1, wherein R1 represents oxygen, nitrogen. The substituent R2, wherein R2 represents a branched or straight chain alkyl group having from 1 to 4 carbon atoms, said alkyl group being substituted with at least one substituent selected from the group consisting of a carboxyl, hydrogen, substituted phenyl, benzyl and substituted benzyl groups or a substituted phenyl group. - Still other objects and advantages of the present invention will become readily apparent to those skilled in this art from the following detailed description wherein I have shown and described only the preferred embodiment of the invention, simply by way of illustration of the best mode contemplated by carrying out my invention. As will be realized, the invention is capable of modification in various obvious respects all without departing from the invention. Accordingly, the drawings and description of the preferred embodiment are to be regarded as illustrative in nature, and not as restrictive.
- FIG. 1 shows the structural of 10-substituted 1,5-dichloro-9(10H)-anthracenones of
formula 3. - FIG. 2 shows the structural of 9-
acyloxy 1,5-dichloroanthracenes and 9-acyloxy 1,8-dichloroanthracene. - FIG. 3 (Scheme 1) shows the synthesis step of the target 10-substituted 1,5-dichloro-9(10H)-anthracenones of
formula 3. - FIG. 4 shows X-ray crystal structure of
compounds 6. - While the invention is susceptible of various modifications and alternative constructions, certain illustrated embodiments thereof have been shown in the drawings and will be described below in detail. It should be understood, however, that there is no intention to limit the invention to the specific form disclosed, but, on the contrary, the invention is to cover all modifications, alternative constructions, and equivalents falling within the spirit and scope of the invention as defined in the claims.
- The 1,5-dichloro-9(10H)-anthracenones bearing O-linked and N-lined substituents that presents as
formula 3 as defined below, said compound containing substituent R1, wherein R1 represents oxygen, nitrogen. The substituent R2, wherein R2 represents a branched or straight chain alkyl group having from 1 to 4 carbon atoms, said alkyl group being substituted with at least one substituent selected from the group consisting of a carboxyl, hydrogen, substituted phenyl, benzyl and substituted benzyl groups or a substituted phenyl group. - Introduction of side chains onto the anthracenone nucleus is usually accomplished by a stepwise procedure via the anthracenedione because of the chemical instability of many anthracenones. Therefore, reduction of 1,5-dichloroanthraquinone and bromination are required in the synthesis of C-10-substituted anthracenones. Although several excellent methods are available for the reduction of anthracenediones, many reducing systems do not lead directly to the anthracene stage. Criswell T. R., et al., J. Org. Chem., vol. 39, p. 770 (1974); Shyamasundar N., et al., J. Org. Chem., vol. 46, pp. 809-811, 1552-1557 (1981).
- The traditionally employed methods that lead preferentially to the anthracenones include stannous chloride in acetic acid/hydrochloric acid there were reported by Müller K., et al., J. Med. Chem., vol. 39, pp. 3132-3138 (1996); Prinz H., et al., J. Org. Chem., vol. 61, pp. 2853-2856 (1996). Thus, treatment of
compound 5 with bromine provide 10-Bromo 1,5-dichloro-9(10H)-anthracenone (6) which have prepared by Müller K., et al., J. Med. Chem., vol. 39, pp. 3132-3138 (1996). Bromination of anthracenone take place at the 10-position. The structure of compound (6) was confirmed by X-ray analysis. The ORTEP plot of compound (6) is shown in FIG. 4; the bond lengths and bond angles for this structure are listed in experimental. A series of 10-substituted 1,8-dichloro-9(10H)-anthracenones were synthesized from compound (6) by nucleophilic substitution at C-10 with 1.5-2.0 equivalents of appropriate amines or alcohols in the presence of catalytic amounts of CaCO3, which strongly reduced the reaction time as compared to the noncatalyzed reaction. The 10-oxy-substituted and 10-N-substituted 1,8-dichloro-9(10H)-anthracenones were synthesized readily according to scheme 1 (FIG. 3). - The structures of these compounds were established on the basis of spectroscopic analysis. The1H-NMR spectra of compound (6) show a singlet at δ 6.62 for the C-10 of H, doublet at δ 8.11 for the proton at
position 8 and dd at δ 7.65 for the proton atposition 6. Of particular importance of these series compounds are the one proton chemical shifts at position 10 between δ 5.31 and 6.08, which are difference from the range of thecompound 5 possessing two 10-H protons at δ 4.32, and the IR stretching frequency which is indicative of C═O stretch. Furthermore, the 13C-NMR spectra of these compounds show the usual carbonyl absorbance signal in the δ 180-190 region. Bhawal B. M., et al., J. Org. Chem., vol. 56, pp. 2846-2849 (1991). - In the previous papers, we described the synthesis and some biological evaluation for 9-
acyloxy 1,5-dichloroanthracenes and 9-acyloxy 1,8-dichloroanthracenes, respectively. In general, results from these assays did not show a reasonable correlation. - We evaluated the ability of the compounds to inhibit the growth of human oral epidermoid carcinoma cells (KB cell line), human cervical carcinoma cells of ME 180 (GBM8401) and Chinese hamster ovary (CHO) cells as normal cells, and lipid peroxidation in model membranes, respectively. The compounds were tested for cytotoxic activity assay as demonstrated by reduction in cell number over time as compared to control plates. The results are shown in Table 1.
- Our study on the cytotoxicity evaluation of 10-substituted 1,8-dichloro-9(10H)-anthracenone derivatives have revealed that compounds 4a, 4c and 4d exhibited high cytotoxicity and significant activity on GBM in vitro assay; compounds 3c, 4b and 4c exhibited high cytotoxicity and significant activity on KB in vitro assay. Only compounds 3a, 4c and 4d were more toxic in CHO than mitoxantrone. Although there were no obvious requirements for potent antiproliferative activity, the inhibitory effects of these compounds appear to be due to some selective cell lines rather than nonspecific redox properties. In addition to the redox properties, other factors such as an appropriate geometry of the molecules when bound to the active site of the substrate may be responsible for the cell growth inhibitory activities of the novel anthracenone and anthracene analogs.
- The inhibitory effect on lipid peroxidation of these compounds were evaluated with rat brain phospholipid liposomes which provide an ideal model system for lipid peroxidation studies by Teng C. M., et. al., Eur. J. Pharmacol., vol. 303, pp. 129-139 (1996). When compared to the ascorbic acid, (+)-α-tocopherol and mitoxantrone, we found better inhibitory effect in 0.5 mM by compounds 4b and 4d (Table 2).
- Furthermore, compounds 4b and 4d were significantly more efficient than ascorbic acid, (+)-α-tocopherol and mitoxantrone in 0.005 mM (Table 3).
- Although not a potent inhibitor of lipid peroxidation in itself, can provide a useful template for the design of potential anticancer agents. Moreover, the results support our hypothesis that structural modification of 1,5-dichloro-9(10H)-anthracenone may lead to control of the release of active oxygen species. In fight of these finding it is suggested that cytoyoxicity activity and lipid peroxidation alone is not sufficient for potent antiproliferative action.
- Whatever the molecular mechanism of the antiproliferative action of anthracenones and wherever its locus, the results described herein indicate that it is sensitive to the slightest modification in the structure of anthracenone and that active analogs can only be made if the anthracenone moiety itself is retained. In conclusion, we have presented 10-substituted 1,8-dichloro-9(10H)-anthracenone derivatives which show potent inhibition of some selective cell lines. In order to understand whether or not these compounds have potent antitumor and biological activities, we will examined their effects in other tests and the results will be reported elsewhere.
- All temperatures are reported in degrees centigrade. Melting points were determined with a Büchi B-545 melting point apparatus and are uncorrected. Chromatography refers to column chromatography using silica gel (E. Merck, 70-230 mesh).1H-NMR spectra were recorded with a Varian GEMR-H-300 (300 MHz); δ values are in ppm relative to a tetramethylsilane internal standard. Fourier-transform IR spectra (KBr) were recorded on a Perkin-Elmer 983G spectrometer. Mass spectra (EI, 70 eV, unless otherwise stated) were obtained on a Finnigan MAT TSQ-46 and Finnigan MAT TSQ-700. UV spectra were recorded on a Shimadzu UV-160.
- The compound of this invention will include various excipients; carriers or diluents and pharmaceutically approved pH of processed salts in accordance to necessity to form composition with therapeutic efficacy. Such pharmaceutical preparation could be in solid form for oral and rectum administration; liquid form or non-intestinal injection form; or ointment form for direct application on affected part. Such solid forms are manufactured according to common pharmaceutical preparation methods, which will include disintegrant like starch; sodium carboxymethyl cellulose, adhesive like ethanol; glycerine, or magnesium stearic acid; lactose to make into pharmaceutical preparation like tablets or filled into capsules or suppository. Solution or saline that include this invention compound as ingredient could use buffers of phosphoric nature to adjust the pH to suitable level, before adding adjutant; emulsifier to produce injection dose or other liquid preparation. This invention compound or pharmaceutical manufacturing could mixed synthetic acid salts with various fundamental preparations to form ointments according to known pharmaceutical manufacturing methods. Pharmaceutical compounds manufactured with this invention compound being the major ingredient could be used on mammals to produce the efficacy of this main ingredient. General dosage could be adjusted according to the degree of symptoms, and normally a person will require 50 to 300 mg each time, three times per day.
- Cytotoxic Activity Test. Human oral epidermoid carcinoma cells (KB cell line), human cervical carcinoma cells of ME 180 (GBM8401) and Chinese hamster ovary (CHO) cells grown in plateau phase were cultivated, and the cell proliferation assay was performed as previously described. Inhibition of cellular growth was calculated by comparison of the mean values of the test compound (N=3) with the control (N=6-8) activity: (1-test compound/control)×100.
- Assay of Lipid Peroxidation. Rat brain homogenate was prepared from the brains of freshly killed Wistar rats and its peroxidation in the presence of iron ions was measured by the thiobarbituric acid (TB A) method as described. The extent of lipid peroxidation was estimated as thiobarbituric acid-reactive substances and was read at 532 nm in a spectrophotometer (Shimnadzu UV-160). The results of this assay are provided in tables 2 and 3.
- The following examples are representative of the practice of the invention.
- 10-
Bromo 1,5-dichloro-9(10H)-anthracenone (6) to a solution of 1,5-dichloro-9(10H)-anthracenone (16.0 mmol) in CS2 (30 ml) was added dropwise a solution of bromine (20.0 mmol) in CS2 (5 ml). The reaction mixture was refluxed for 1 h. The reaction mixture was allowed to cool, filtered, and the filtrate was evaporated to dryness. The remaining crude product was dissolved in dichloromethane. The combined organic extracts were washed with water and dried (MgSO4), and the solution was concentrated. The resulting precipitate was collected by filtration, and further purified by crystallization and chromatography to give the corresponding product. - C14H7BrCl2O, Mt=342.01. A needle of the approximate dimensions 0.5×0.4×0.12 mm was mounted to glass fiber along its longest axis. The crystal system was triclinic, space group P-1. Cell constants a=7.6092(13), b=8.5639(14), and c=10.0242(14) Å; α=76.212(11)°; β=73.058(12)°; γ=87.135(12)°; V=606.7(2) Å3; Z=2; μ(Mo Kα)=3.809 cm−1; F(000)=336. Cell dimensions were determined using a Nonious CAD4 Kappa Axis XRD & Siemens Smart CCD XRD diffractometer equipped with a graphite monochromator and molybdenum source (λ=7.1073 Å). Data were collected on the same instrument using ω scans with 2θ varied from 2-50°. A total of 3090 unique reflexions were determined of which 1647 were >2.0σ. The structure was solved using direct methods and was refined using standard techniques. A total of 235 parameters were varied in the final least-squares. The refinement converged at R=0.040 and Rw=0.040. Residual electron density varied from 0.20 to −0.20 e/Å3.
- To a solution of compound (6) (2.0 mmol) and anhydrous calcium carbonate (0.5 g) in dry THF (20 ml) was added dropwise a solution of an appropriate alcohol or amine (3 mmol) in dry THF (10 ml) under N2. The reaction mixture was stirred at room temperature or refluxed for several hours. Water (250 ml) was added and then extracted with dichloromethane. The combined organic extracts were washed with water, dried (MgSO4), and concentrated. The resulting precipitate was collected by filtration, washed with water and further purified by crystallization and chromatography.
- To a solution of compound (6) (2.0 mmol) and anhydrous calcium carbonate (0.5 g) in dry THF (20 ml) was added dropwise a solution of an appropriate propanol (10 ml) in dry THF (10 ml) under N2. The reaction mixture was refluxed for 3 hours. Water (250 ml) was added and then extracted with dichloromethane. The combined organic extracts were washed with water, dried (MgSO4), and concentrated. The resulting precipitate was collected by filtration, washed with water and further purified by crystallization (CH3CN).
- To a solution of compound (6) (2.0 mmol) and anhydrous calcium carbonate (0.5 g) in dry THF (20 ml) was added dropwise a solution of an appropriate iso-butanol (10 ml) in dry THF (10 ml) under N2. The reaction mixture was refluxed for 3 hours. Water (250 ml) was added and then extracted with dichloromethane. The combined organic extracts were washed with water, dried (MgSO4), and concentrated. The resulting precipitate was collected by filtration, washed with water and further purified by crystallization (CH3CN).
- To a solution of compound (6) (2.0 mmol) in dry THF (20 ml) was added dropwise a solution of o-toluidine (10 ml) in dry THF (10 ml) under N2. The reaction mixture was stirred at room temperature for 24 hours. Water (250 ml) was added and then extracted with dichloromethane. The combined organic extracts were washed with water, dried (MgSO4), and concentrated. The resulting precipitate was collected by filtration, washed with water and further purified by crystallization (CH3CN).
TABLE 1 In Vitro Cytotoxicity Activity of 10-Substituted 1,5-Dichloro-9(10H)- anthracenones IC50 (μM)a Compound X-R GBMb KBc CHOd 3a OCH3 23.5 8.8 2.9 3b OCH2CH3 21.8 6.1 5.8 3c OCH2CH2CH3 11.1 1.8 42.0 3d OCH(CH3)2 65.4 21.8 15.2 3e OCH2CH2CH2CH3 29.5 29.5 8.0 3f OCH2CH(CH3)2 43.2 14.7 20.1 3g OCH2C6H5 18.5 93.4 24.7 4a N(CH2CH3)2 7.5 17.2 15.0 4b NH(C6H4)CH3(m) 11.2 9.5 6.2 4c NH(C6H4)CH3(o) 2.4 3.4 3.8 4d NH(C6H4)CH3(p) 4.6 11.3 3.0 mitoxantrone- 1.5 1.7 4.0 HCl -
TABLE 2 Inhibitory Effect of 10-Substituted 1,5-Dichloro-9(10H)-anthracenones of the Invention on Iron-induced Lipid Peroxidation in Rat Brain Homogenates. Compound X R Inhibition % (0.5 mM)a 3a O CH 3 7 ± 0.1 3b O CH2CH3 7 ± 0.1 3c O CH2CH2CH3 29 ± 2.5 3d O CH(CH3)2 13 ± 1.3 3e O CH2CH2CH2CH3 31 ± 3.7 3f O CH2CH(CH3)2 38 ± 3.1 3g O CH2C6H5 16 ± 1.5 4a N (CH2CH3)2 12 ± 1.4 4b NH (C6H4)CH3(m) 100 4c NH (C6H4)CH3(o) 73 ± 3.5 4d NH (C6H4)CH3(p) 100 ascorbic acid 87 ± 3.1 (+)-α-tocopherol 53 ± 4.4 mitoxantrone-HCl 64 ± 2.8 -
TABLE 3 Inhibitory Effects of 4b and 4d on Iron-induced Lipid Peroxidation in Rat Brain Homogenates. Inhibition (%)a Compound 5 mM 0.5 mM 0.05 mM 0.005 mM 4b 100 100 92 ± 4.1 23 ± 2.4 4d 100 100 94 ± 3.5 33 ± 2.7 ascorbic acid 100 87 ± 2.5 22 ± 2.2 7 ± 0.5 (+)-α-tocopherol 100 53 ± 1.7 0 0 mitoxantrone-HCl 100 64 ± 2.1 52 ± 3.5 10 ± 1.1 -
TABLE 4 Physicochemical data of the synthetic compounds 10- Bromo 1,5-dichloro-9(10H)-anthracenone (6)yield 95% mp. 201-202° C. MS m/z: 341(M+), 261 IR (KBr) cm−1 1670. UV λmax (CHCl3) nm 295(4.57) (log ε) 1H-NMR(CDCl3) δ: 8.11(1H, d, J=7.1Hz), 7.65(1H, dd, J=1.2, 8.0Hz), 7.61-7.46(4H, m), 6.62(1H, s) 10- Methoxy 1,5-dichloro-9(10H)-anthracenone (3a)yield 90% mp. 170-171° C. Anal. Calcd .For C, 49.15; H, 3.44 Found: C, 49.41; H, 3.21 C15H10O2Cl2: UV λmax (CHCl3) nm 282(4.72) (log ε) MS m/z: 292(M+), 261 IR (KBr) cm−1 1670, 1068 1H-NMR(CDCl3) δ: 8.04(1H, dd, J=0.9, 7.6Hz), 7.63(1H, dd, J=1.0, 7.4Hz), 7.55(1H, dd, J=2.3, 6.6Hz), 7.52(1H, d, J=2.5Hz), 7.51(1H, t, J=7.3Hz), 7.45(1H, t, J=7.8Hz), 5.76(1H, s), 3.1(3H, s). 13C-NMR (CDCl3) δ: 183.55, 141.99, 137.13, 135.76, 135.37, 134.94, 134.39, 133.60, 133.36, 130.65, 130.18, 129.28, 126.76, 72.52, 54.67. 10- Ethoxy 1,5-dichloro-9(10H)-anthracenone (3b)yield 95% mp. 153-154° C. Anal. Calcd .For C, 62.54; H, 3.94 Found: C, 62.18; H, 3.85 C16H12O2Cl2: UV λmax (CHCl3) nm 280(4.88) (log ε) MS m/z: 306(M+), 261 IR (KBr) cm−1 1678, 1069 1H-NMR(CDCl3) δ: 8.03(1H, dd, J=0.8, 7.6Hz), 7.61(1H, dd, J=0.8, 7.6Hz), 7.54(1H, dd, J=2.1, 6.6Hz), 7.51(1H, d, J=5.7Hz), 7.49(1H, t, J=7.7Hz), 7.43(1H, t, J=7.8Hz), 5.79(1H, s), 3.32-3.25(2H, m), 1.04(3H, t, J=6.9Hz) 13C-NMR (CDCl3) δ: 183.67, 142.67, 137.06, 136.35, 135.26, 134.85, 134.31, 133.52, 133.16, 130.47, 130.07, 129.17, 126.71, 71.66, 62.87, 15.76. 10- Propyloxy 1,5-dichloro-9(10H)-anthracenone (3c)yield 62% mp. 98-99° C. Anal. Calcd .For C, 63.55; H, 4.39 Found: C, 63.28; H, 4.23 C17H14O2Cl2: UV λmax (CHCl3) nm 281(4.66) (log ε) MS m/z: 320(M+), 261 IR (KBr) cm−1 1678, 1051 1H-NMR(CDCl3) δ: 8.04(1H, dd, J=0.8, 7.6Hz), 7.62(1H, dd, J=0.9, 7.6Hz), 7.55(1H, dd, J=2.2, 6.5Hz), 7.52-7.48(2H, m), 7.44(1H, t, J=7.7, 7.9Hz), 5.82(1H, s), 3.14(2H, t, J=6.4Hz), 1.44-1.37(2H, m), 0.73(3H, t, J=7.2, 7.4Hz). 13C-NMR (CDCl3) δ: 183.65, 142.74, 137.08, 136.33, 135.22, 134.92, 134.35, 133.54, 133.14, 130.46, 130.09, 129.23, 71.60, 68.75, 23.45, 11.07 10-(2-Propyloxy) 1,5-dichloro-9(10H)-anthracenone (3d) yield 58% mp. 172-173° C. Anal. Calcd .For C, 62.54; H, 3.94 Found: C, 62.32; H, 3.73 C17H14O2Cl2: UV λmax (CHCl3) nm 287(4.77) (log ε) MS m/z: 320(M+), 261 IR (KBr) cm−1 1679, 1016 1H-NMR(CDCl3) δ: 7.99(1H, dd, J=0.9, 7.6Hz), 7.58(1H, dd, J=1.0, 7.6Hz), 7.50(1H, dd, J=2.6, 7.0Hz), 7.48-7.44(2H, m), 7.41(1H, t, J=7.8Hz), 5.83(1H, s), 3.6(1H, m), 1.06-0.88(6H, dd, J=6.0, 6.1Hz) 13C-NMR (CDCl3) δ: 84.19, 143.29, 137.43, 137.22, 134.19, 134.42, 134.06, 133.23, 133.02, 130.39, 129.05, 126.84, 69.64, 68.81, 23.61, 22.80. 10-(Butyloxy) 1,5-dichloro-9(10H)-anthracenone (3e) yield 50% mp. 117-118° C. Anal. Calcd .For C, 64.48; H, 4.81 Found: C, 64.21; H, 4.89 C18H16O2Cl2: UV λmax (CHCl3) nm 280(4.84) (log ε) MS m/z: 334(M+), 261 IR (KBr) cm−1 1678, 1060 1H-NMR(CDCl3) δ: 8.04(1H, dd, J=0.9, 7.7Hz), 7.61(1H, dd, J=1.0, 7.7Hz), 7.55(1H, dd, J=2.2, 6.5Hz), 7.52-7.48(2H, m), 7.44(1H, t, J=7.8Hz), 5.81(1H, s), 3.18(2H, t, J=6.3Hz), 1.36(2H, m), 1.17(2H, m), 0.72(3H, t, J=7.4Hz) 13C-NMR (CDCl3) δ: 183.66, 142.78, 137.12, 136.34, 135.24, 134.91, 134.33, 133.50, 133.13, 130.44, 130.13, 129.20, 126.67, 71.58, 66.63, 32.24, 19.66, 14.14 10-(iso-Butyloxy) 1,5-dichloro-9(10H)-anthracenone (3f) yield 65% mp. 146-147° C. Anal. Calcd .For C, 64.48; H, 4.81 Found: C, 64.23; H, 4.75 C18H16O2Cl2: UV λmax (CHCl3) nm 281(4.55) (log ε) MS m/z: 334(M+), 261 IR (KBr) cm−1 1681, 1056 1H-NMR(CDCl3) δ: 8.04(1H, dd, J=0.8, 7.9Hz), 7.62(1H, dd, J=0.9, 7.6Hz), 7.55(1H, dd, J=2.4, 6.3Hz), 7.53(1H, d, J=6.1Hz), 7.50(1H, t, J=6.5Hz), 7.44(1H, t, J=7.8Hz), 5.83(1H, s), 2.92-2.87(2H, m), 1.66-1.54(1H, m), 0.70(6H, t, J=6.8, 6.7Hz) 13C-NMR (CDCl3) δ: 183.62, 142.78, 137.07, 136.29, 135.18, 134.95, 134.36, 133.54, 133.11, 130.43, 130.09, 129.26, 126.61, 73.50, 71.52, 29.03, 19.84, 19.79 10-Benzyloxy 1,5-dichloro-9(10H)-anthracenone (3g) yield 75% mp. 150-151° C. Anal. Calcd .For C, 68.29; H, 3.82 Found: C, 68.18; H, 3.68 C21H14O2Cl2: UV λmax (CHCl3) nm 280(4.83) (log ε) MS m/z: 368(M+), 261 IR (KBr) cm−1 1676, 1047 1H-NMR(CDCl3) δ: 8.05(1H, d, J=7.6Hz), 7.62(1H, d, J=8.0Hz), 7.57(1H, d, J=6.9Hz), 7.55-7.51(2H, m), 7.45(1H, t, J=7.8Hz), 7.23-7.14(5H, m), 5.96(1H, s), 4.27(2H, dd, J=6.5, 10.9Hz) 13C-NMR (CDCl3) δ: 183.56, 142.32, 137.96, 137.21, 136.09, 135.41, 134.91, 134.43, 133.64, 133.38, 130.69, 130.20, 129.38, 128.85, 128.43, 128.34, 126.83, 71.57, 69.29 10- Diethylamino 1,5-dichloro-9(10H)-anthracenone (4a)yield 64% mp. 192-193° C. Anal. Calcd .For 64.67; H, 5.12 Found: C, 64.48; H, 5.35 C18H17NOCl2: UV λmax (CHCl3) nm 275(4.97 (log ε) MS m/z: 333(M+), 261 IR (KBr) cm−1 1674, 1299 1H-NMR(CDCl3) δ: 8.07(1H, dd, J=1.9, 7.7Hz), 7.59(1H, dd, J=1.0, 7.8Hz), 7.47-7.31(4H, m), 5.31(1H, s), 2.59-2.20(4H, m), 0.92(6H, t, J=7.0Hz) δ: 184.67, 142.83, 138.91, 138.00, 134.96, 134.25, 132.71, 131.96, 130.79, 129.30, 128.56, 125.91 58.04, 44.06, 14.13 10-(m-Toluidino) 1,5-dichloro-9(10H)-anthracenone (4b) yield 66% mp. 186-188° C. Anal. Calcd .For C, 68.48; H, 4.10 Found: C, 68.27; H, 4.35 C21H15NOCl2: UV λmax (CHCl3) nm 272(5.17) (log ε) MS m/z: 367(M+), 261 IR (KBr) cm−1 3359, 1664 1H-NMR(CDCl3) δ: 8.08(1H, dd, J=1.0, 7.7Hz), 7.65(1H, dd, J=1.2, 7.8Hz), 7.50-7.33(4H, m), 7.07(1H, t, J=7.8Hz), 6.61(1H, s), 6.63(1H, s), 6.56(1H, s), 6.05(1H, s), 3.72(1H, s), 2.26(3H, s). 13C-NMR (CDCl3) δ:183.56, 146.28, 145.88, 139.73, 138.20, 136.22, 135.35, 134.71, 134.55, 133.92, 132.50, 129.87, 129.76, 128.41, 127.54, 126.85, 121.14, 117.38, 113.30, 52.63, 22.12. MS m/z: 10-(o-Toluidino) 1,5-dichloro-9(10H)-anthracenone (4c) yield 58% mp. 193-195° C. Anal. Calcd .For C, 68.48; H, 4.10 Found: C, 68.19; H, 4.26 C21H15NOCl2: UV λmax (CHCl3) nm 276(5.24) (log ε) MS m/z: 367(M+), 261 IR (KBr) cm−1 3402, 1658 1H-NMR(CDCl3) δ: 8.12(1H, dd, J=0.8, 8.4Hz), 7.66(1H, dd, J=1.3, 7.9Hz), 7.50-7.26(4H, m), 7.16(1H, d, J=4.1Hz), 7.01(1H, d, J=7.4Hz), 6.77-6.72(2H, m), 6.08(1H, s), 3.68(1H, s), 1.87(3H, s). 13C-NMR (CDCl3) δ:183.56, 146.02, 144.37, 138.31, 136.31, 135.39, 134.79, 134.63, 133.89, 132.52, 131.30, 129.96, 127.62, 127.34, 126.94, 125.21, 119.97, 114.76, 114.72, 52.89, 17.98 10-(p-Toluidino) 1,5-dichloro-9(10H)-anthracenone (4d) yield 73% mp. 189-191° C. Anal. Calcd .For C, 68.48; H, 4.10 Found: C, 68.56; H, 4.23. C21H15NOCl2: UV λmax (CHCl3) nm 275(5.09) (log ε) MS m/z: 367(M+), 261 IR (KBr) cm−1 3381, 1658 1H-NMR(CDCl3) δ: 8.06(1H, dd, J=1.0, 7.8Hz), 7.65(1H, dd, J=1.2, 7.9Hz), 7.46-7.40(3H, m), 7.35(1H, t, J=7.2Hz), 6.97(2H, d, J=8.0Hz), 6.65(2H, d, J=8.3Hz), 5.97(1H, s), 3.69(1H, s), 2.23(3H, s). 13C-NMR (CDCl3) δ:183.54, 145.79, 143.76, 138.25, 136.24, 135.33, 134.69, 134.47, 133.82, 132.46, 130.43, 129.92, 129.84, 128.47, 127.66, 126.85, 117.24, 53.44, 21.07. - While there is shown and described the present preferred embodiment of the invention, it is to be distinctly understood that this invention is not limited thereto but may be variously embodied to practice within the scope of the following claims. From the foregoing description, it will be apparent that various changes may be made without departing from the spirit and scope of the invention as defined by the following claims.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/965,774 US6596774B1 (en) | 2001-09-27 | 2001-09-27 | Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/965,774 US6596774B1 (en) | 2001-09-27 | 2001-09-27 | Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030135060A1 true US20030135060A1 (en) | 2003-07-17 |
US6596774B1 US6596774B1 (en) | 2003-07-22 |
Family
ID=25510472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/965,774 Expired - Lifetime US6596774B1 (en) | 2001-09-27 | 2001-09-27 | Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives |
Country Status (1)
Country | Link |
---|---|
US (1) | US6596774B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI378792B (en) * | 2008-04-02 | 2012-12-11 | Nat Defense Medical Ct | Synthesis, telomerase inhibition and cytotoxic studies on 2,7-disubstituted anthraquinone derivatives |
TWI422367B (en) * | 2008-11-28 | 2014-01-11 | Nat Defense Medical Ct | An onion quinone derivative for inhibiting cancer and a method for producing the same |
-
2001
- 2001-09-27 US US09/965,774 patent/US6596774B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6596774B1 (en) | 2003-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0611564A2 (en) | purine derivatives by substitution of n2-quinoline or isoquinoline and their methods of preparation and uses | |
MXPA06004076A (en) | Method for the production of amino crotonyl compounds. | |
CN113336705B (en) | Cannabidiol-2-imidazole-1-formate and application thereof | |
FI67686B (en) | PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC ANIMAL PRODUCTS | |
EP2269994B1 (en) | The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof | |
EP0040401A1 (en) | Triazoloquinoxalin-4-ones and such oxaline-4-thiones | |
WO1985000368A1 (en) | Allopurinol prodrugs | |
WO2017000379A1 (en) | Silicon phthalocyanine complex, and preparation method and pharmaceutical application thereof | |
CN111704646B (en) | Steroid compound and preparation method and application thereof | |
EP2388248B1 (en) | Methods for the preparation of ivabradine sulfate and form i crystal thereof | |
WO2018086242A1 (en) | Ph-sensitive axially-substituted silicon phthalocyanine complex, preparation method therefor, and medical application thereof | |
NZ227149A (en) | (2-piperazinyl)-2-oxoethylene-substituted flavonoid derivatives and pharmaceutical compositions | |
JP4980431B2 (en) | Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same | |
US6596774B1 (en) | Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives | |
KR101208956B1 (en) | Erlotinib dichloroacetate and anti-cancer agent comprising the same | |
KR100372312B1 (en) | Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same | |
AU2005318227B2 (en) | Stereoselective process and crystalline forms of a camptothecin | |
CN109761997B (en) | Preparation and application of bis-fluoroquinolone thiadiazole urea N-methyl lomefloxacin derivative | |
WO2020224208A1 (en) | Pyridone derivative crystal form and preparation method and application therefor | |
WO2011001383A1 (en) | Crystalline form of fosamprenavir calcium | |
ES2207296T3 (en) | SODIUM SALT OF 3- (4-CINAMIL-1-PIPERAZINIL) IMINO-METHYL RIFAMYCIN SV AND PREPARATION PROCEDURE. | |
JPH01110680A (en) | 1,2,3,4-tetrahydroisoquinoline antiarrhythmic | |
CN112939864B (en) | Spiro [ benzo [ c ] aza-1, 1' -cyclohexyl ] -3-ones | |
CN113773356B (en) | Picroside II derivative and preparation method and application thereof | |
CN114213501B (en) | C-23 nitrogen-containing heterocyclic derivative of cycloisoxazole ring hederagenin and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REMI | Maintenance fee reminder mailed | ||
REIN | Reinstatement after maintenance fee payment confirmed | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20070722 |
|
AS | Assignment |
Owner name: NATIONAL DEFENSE MEDICAL CENTER, TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUANG, HSU-SHAN;REEL/FRAME:022990/0143 Effective date: 20090722 |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
PRDP | Patent reinstated due to the acceptance of a late maintenance fee |
Effective date: 20100326 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: NATIONAL SCIENCE COUNCIL OF R.O.C., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NATIONAL DEFENSE MEDICAL CENTER;REEL/FRAME:027341/0233 Effective date: 20111116 |
|
FPAY | Fee payment |
Year of fee payment: 12 |